INTRODUCTION

Since the initial recognition of COVID-19 in the world in 2019, tremendous advances have taken place in the understanding of the dreaded diseases as regarding its epidemiology, etiology, immunology, Pathophysiology, clinical feature, and morphology changes in various tissues and organs of the body. Although antiretroviral therapy is being widely used all over the world for such patents, effects at finding a 2019 Novel Coronavirus (SARS-CoV-2) vaccine have not succeeded. Human pathogenic subtypes of a coronavirus are associated with mild clinical manifestations. However, SARS-CoV and MERS-CoV are two important exceptions. In 2012, MERS-CoV was first seen in Saudi Arabia. He was responsible for 2,494 confirmed cases, leaving 858 people dead. In 2002, a subtype of the Corona beta virus spread rapidly in Guangdong, China. This epidemic has claimed 8,000 deaths and 774 deaths in 37 countries (Lu et al., 2020). The epidemic of 2020 was detected as pneumonia of unknown etiologic in Wuhan, China. Extensive studies and laboratory research have identified the offender as a new strain of a coronavirus (Adhikari et al., 2020).

Initially, this virus was classified as SARS-CoV-2. However, the virus was classified by the International Commission for Viruses Classification as CoV-2. On February 11th, 2020, the World Health Organization (WHO) announced that the disease caused by this new virus was Coronavirus 2019 (COVID-19). The emergence and outbreak of frequent coronaviruses pose a public health threat. This recommends that CoVs that originate from one animal to another can be transferred from one person to another. The ongoing changes in the

Abstract

Initially recognized of COVID-19 within the world in 2019, the World Health Organization situational report from May 22nd, 2020, globally, there is a complete of 5,204,508 confirmed cases, with 212 countries being affected by the novel coronavirus. 2019 novel coronavirus (SARS-CoV-2) is that the seventh member of the family of coronaviruses is enveloped viruses with a positive sense, single-stranded RNA genome. The SARS-CoV-2 may be a β-CoV of group 2B there is 70% comparability in genetic sequence to SARS-CoV. The source of the new coronavirus infection has been resolved as bats. With whole-genome sequences of SARS-CoV-2 is 96% comparatively at the whole-genome level to a bat coronavirus. Mechanisms of transmission are concluded to incorporate contact, droplet, and possibly airborne under certain circumstances supported ancient experiences associated with SARS-CoV outbreaks. Although antiretroviral therapy is being widely used everywhere the globe for such patents, effects at finding a SARS-CoV vaccine haven’t succeeded so far.

Received: May 26th, 2020
Accepted: June 17th, 2020
Published: June 22nd, 2020
environment and climate make the emergence of such infections in the future more likely (Hassan et al., 2020).

**EPIDEMIOLOGY**

COVID-19 is pandemic in the spread and is seen in all continents. As per the WHO global report 2019, a novel coronavirus recognizing SARS-CoV-2. This is likely the third time in three decades that a zoonotic coronavirus has fall from infecting animals to humans. As of May 25th, 2020, 337,687 have died, and 5,204,508 have been infected globally with the center of the outbreak being located in Wuhan but now having spread, with confirmed cases 212 other countries (Worldometer, 2020). While the fatality rate of SARS-CoV-2 is less than other recent respiratory virus outbreaks, it rests much higher than other commonly encountered causes of respiratory infection but its full impact is yet undetermined. The WHO has now conformed the coronavirus outbreak to be a public health emergency of international concern (Long & Ehrenfeld, 2020). Most infected countries' data of COVID-19 are summarized in Figure 1.

Many studies show more clearly that the death rate increases with age, and children younger than 9 years do not appear to be affected significantly, without symptoms or mild symptoms or none of them died due to a COVID-19 infection. For 80-year-olds, about 14.80% of people die as presented in Figure 2. Mortality begins to increase for those over 50 years of age. The death rate among people under fifty is 0.02%, while it is 0.8% for those aged 18-44. For ages 45 to 64 years, the ratio is 3.60%, for ages 65 to 79 years is 8.00% and for people over 80 years old is 14.8% (Worldometer, 2020).

The elderly and young people, who suffer from serious diseases, such as diabetes and heart and lung diseases, are at risk of developing a serious disease if they have a coronavirus. The death rate for those without pre-existing conditions is around 1%. The Centers for Disease Control and Prevention has published specific guidelines for people in these categories (Hafeez et al., 2020). For people with cardiovascular disease, the death rate is 13.2%, for diabetes 9.2%, for chronic respiratory diseases (such as asthma and chronic lung disease) 8.0%, for high blood pressure (high blood level) 8.4%, and the cancer death rate 7.6%. The data is summarized in Figure 3.
ETIOLOGICAL OF COVID-19

COVID-19 is caused by a single-stranded RNA (retrovirus) virus called the 2019 Novel Coronavirus (SARS-CoV-2). The 2019 Novel Coronavirus or 2019-nCoV is called the Wuhan Virus because it is a never before seen mutation of an animal coronavirus first identified in Wuhan, China, on December 30th, 2019. The SARS-CoV-2 is a novel human coronavirus in further to similar coronavirus 229E, NL 63, OC43, HKU1, Middle East respiratory syndrome-related coronavirus (MERS-CoV) and severe acute respiratory syndrome-related coronavirus (SARS-CoV) (Zhu et al., 2020). The SARS-CoV-2 is the seventh member of the coronavirus family (Nidovirales arrangement, Coronaviridae family, and Coronavirinae subgroup) are positive-encapsulated viruses, single-chain RNA genome. With genome sizes feeding on 26 to 32 kb in length, coronaviruses possess the largest genomes of human RNA viruses, after MERS-CoV and SARS-CoV (Dhama et al., 2014; Hui et al., 2020). Thanks to the genome sequencing, the nCoV 2019 gene sequencing became available to the WHO, which enabled various laboratories to produce a diagnostic test for the reverse transcription of a polymerase chain reaction (RT-PCR) specifically for detection of viral DNA. The SARS-CoV-2 is the 2B β-CoV group. With genetic comparability of more than 70% with SARS-CoV (Li et al., 2020). Coronaviruses have begun two large-scale pandemics in the past two decades, SARS and the Middle East respiratory syndrome (MERS) (Drosten et al., 2003; Zaki et al., 2012). It has commonly been thought that SARS-CoV-2 which is found in bats could cause a disease outbreak (Fan et al., 2019; Schoeman & Fielding, 2019).

ORIGIN OF SARS-CoV-2

The source of the new coronavirus infection has been resolved as a racket. With the entire genome, the SARS-CoV-2 sequences are 96% identical at the full genome level of the interactive Coronavirus (Zhou et al., 2020). Wu and his colleagues note a genetic analysis of the genetic development of the complete viral genome and conclude that the virus was closely related to a group of SARS coronaviruses that were previously sampled on bats in China (Wu et al., 2020a). Ji and colleagues note a complete sequence analysis and comparison in conjunction with the relative polarization of the use of equivalent codon (RSCU) among animal species based on the SARS-CoV-2 RNA genome sequences, and results show that the virus was a combined virus between a bat coronavirus and another unknown origin coronavirus. They also noticed that the snake was the animal’s most likely reservoir due to the RSCU bias of the virus being closest to the snake (Ji et al., 2020). The new coronavirus has demonstrated a similar pattern of infection with other coronaviruses in humans, especially the SARS-CoV and MERS-CoV (Guo et al., 2020; Kumar et al., 2020).

COMPOSITION OF SARS-CoV-2

Coronary viruses are spherical with diameters of approximately 125 nm, as demonstrated in recent studies.
by microscopic tomography and electron microscopy. A major characteristic feature of coronaviruses is that club-dropping points emanate from the surface of the virion. These nails are an explanatory feature of the virion and give it the appearance of a solar aura, which gave the name of a coronavirus. In the shell of the virion is the nucleus. Coronaviruses have a unified helical nucleocapsid, which is not unusual for positive RNA viruses but is more common for negative RNA viruses (Barcena et al., 2009).

The structure of the coronavirus contains four major structural proteins as visualized in Figure 4. These are advanced proteins (S) membranous proteins (M) casing proteins (E) and nucleocapsid proteins (N) all encoded at the three ends of the viral genome. Protein S (~150 kDa), uses the N-terminal signal sequence to access the ER, and it is strongly bound to glycosylate. Homotrimers from the virus-encoded protein S produce a distinct peak structure on the surface of the virus. COVID-19 glycoprotein S could be a first-class fusion protein and a successful binding to the host receptor. In most coronaviruses, S is divided by angry protease in a group of cells into several different peptides denoting S1 (receptor binding domains) and S2 (advanced molecule) (Schoeman & Fielding, 2019).

Protein M is the most abundant structural protein in Freon. It is a very weak protein (~25-30 kDa) with three membranous domains (Molenkamp & Spaan, 1997) and is supposed to transport virion in its shape. It is a low ectodomain N-terminal glycosylated and a much larger C-terminal endo domain extends 6 to 8 nm in the viral structure (Kuo & Masters, 2013). Although the translation is common to the ER membrane, most M proteins do not have the code sequence (Hurst et al., 2013).

Protein E (~8-12 kDa) is found in small quantities in the Freon. Coronavirus E proteins vary greatly but have a typical structure (Sturman et al., 1980). The membrane topology for protein E has not been completely resolved, but most data indicate that it is a transmembrane protein. Protein E contains the ectoderm N-terminal field and the C-terminal endodomain and the ion channel activity. Since they are hostile to other structural proteins, recombinant viruses that lack protein E are not always fatal, although this may depend on the type of virus (Klausegger et al., 1999).

Protein N is the only protein found in the nucleus. It consists of two different fields, the N-domain (NTD) and the C-field (CTD), both of which can bind to RNA in the laboratory, but each field uses different mechanisms to link RNA. Protein N is also graters phosphorylated, and phosphorylation has been recommended to make a structural change that improves viral RNA affinity compared to non-viral RNA. Protein N links the viral genome with string-like beads. Specific cRNAs substrates were identified for protein N; TRS and genomic packing signal. Genomic conditioning signal is individually associated with the second domain or the terminal RNA binding field. N protein also binds nsp3 receptor protein, a key component of the replicate complex protein, and the M protein (McBride et al., 2014).

A fifth structural protein, hemagglutinin esterase (HE), is here in a subset of β-CoV. Protein works like hemagglutinin bind to sialic acids with glycoproteins on the surface and contains acetyl esterase activity (Graham et al., 2005). These activities are believed to prolong the entry of cells by protein S and the spread of the virus.
through the mucosa (Cornillez-Ty et al., 2009). Interestingly, it increases the nerve idling of the viral hepatitis virus (MHV) (Chatterjee et al., 2009); however, he chooses against tissue culture for unknown reasons (Egloff et al., 2006).

The ORF1a/b consists of about two-thirds of the viral genome and codes for 16 non-structural proteins as summarized in Table 1. There is a shift in Box-1 between ORF1a and ORF1b, which results in the production of two peptides (pp1a and pp1ab), which are then processed by the viral coded protease at 16 nsp.

### Table 1: Function of non-structural protein of SARS-CoV-2

<table>
<thead>
<tr>
<th>Protein</th>
<th>Function</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSP 1</td>
<td>Promote cellular mRNA degradation with the translation of the host cells prevent innate immune response</td>
<td>Eriksson et al., 2008; Frieman et al., 2009</td>
</tr>
<tr>
<td>NSP 2</td>
<td>There is no known function, linked to the prohibition of proteins</td>
<td>Serrano et al., 2009; Ziebuhr et al., 2001</td>
</tr>
<tr>
<td>NSP 3</td>
<td>Multidomain larger transmembrane proteins interact with activities with protein N promote the expression of cytokines, attach to the viral protein, and block the host’s innate immune response.</td>
<td>Gadlage et al., 2010; Oostra et al., 2008; Egloff et al., 2004</td>
</tr>
<tr>
<td>NSP 4</td>
<td>Potential membrane scaffold protein responsible for providing suitable structure for DMVs</td>
<td>Xu et al., 2003</td>
</tr>
<tr>
<td>NSP 5</td>
<td>Mpro cleavages viral polyprotein</td>
<td>Ivanov &amp; Ziebuhr, 2004</td>
</tr>
<tr>
<td>NSP 6</td>
<td>Potential membrane scaffold protein from translocating viral protein.</td>
<td>Ivanov et al., 2004</td>
</tr>
<tr>
<td>NSP 7</td>
<td>The formation of a super complex hexadecameric with nsp8 could serve as a practical clamp for RNA polymerase</td>
<td>Eckerle et al., 2010</td>
</tr>
<tr>
<td>NSP 8</td>
<td>The formation of a super complex hexadecameric with nsp7 could serve as a practical clamp for RNA polymerase</td>
<td>Eckerle et al., 2007</td>
</tr>
<tr>
<td>NSP 9</td>
<td>Host-based RNA binding protein</td>
<td>Chen et al., 2019</td>
</tr>
<tr>
<td>NSP 10</td>
<td>The cofactor of nsp16 and nsp14 forms heterogeneous modulator with both and enhance Exon and 2-O-MT activity</td>
<td>Bhardwaj et al., 2006</td>
</tr>
<tr>
<td>NSP 11</td>
<td>Cleavage of pp1a at the NSP 10/12 junction</td>
<td>Decroly et al., 2008</td>
</tr>
</tbody>
</table>

### TRANSMISSION ROUTES OF SARS-CoV-2

The coronavirus first announced in December 2019 is now a public health emergency of international concern. Epidemiologists are working to update estimates the number of cases; genome samples of the pathogen are being sequenced and results are being shared (Zheng, 2020). Mechanisms of transmission are concluding to incorporate contact, droplet, and possibly airborne under certain circumstances supported on historical experiences associated with SARS-CoV outbreaks (Yu et al., 2020; Christian et al., 2004).

**Respiratory droplet**

Respiratory infection may be transmitted through droplets of varied sizes; when the droplet partials are smaller than 5-10 µm in diameter, they called respiratory droplets, and after they are smaller than 5 µm in diameter they’re called as droplet nuclei, per present evidence, COVID-19 virus is primarily transmitted between people through respiratory droplets and parson to parson close contact routes. Droplet spread occurs when an individual is in close contact (within a minute) with people who have respiratory symptoms (e.g. coughing or sneezing) and is therefore in danger of getting his/her mucosa (mouth and nose) or conjunctive (eyes) exposed to potentially infective respiratory droplets. Transmission can also occur through fomites with the immediate
environment around the infected parson (Dbouk & Drikakis, 2020).

**Focal-oral routes**

There is some evidence that COVID-19 infection may attend to intestinal infection and be present in fases. However, thus for just one study has cultured the COVID-19 virus from one stool specimen (Zhang et al., 2020a). There are no announced of fecal-oral transmission of the COVID-19 virus thus for. The fundamental reproduction number (R0) for this infection, given variable host and environmental factors, is measurement within the initial outbreak to be between 2.2 and 3.6 (number of cases generated after exposure to at least one patient), which is said to SARS-CoV but on top of MERS-CoV (Zhao et al., 2020).

People who live or travel a lot in Hubei province are at risk of infection. Also, doctors and health officials who are infected to new coronavirus patients have a good chance of contracting the virus, despite appropriate preventive measures. One of the first signs of transmission between people is health care providers who develop the disease.

**PATHOGENESIS OF COVID-19**

The pathogenesis of COVID-19 infection is mostly related to the depletion of type 2 respiratory pneumocyte cells resulting in profound alveoli destruction as visualized in Figure 5.

**Selective tropism for pneumocyte molecular receptor**

The first coronavirus receptors were identified by the MHV receptor as listed in Table II. The MHV binds to the Murine carcinoembryonic antigens related adhesion molecule 1 (mCEACAM1) adhesion molecule (the adhesion molecule of membranous cancer cell antigen) to cell injury. The mCEACAM1 can be a type I membrane protein linked to the immunoglobulin superfamily. The mCEACAM1 can be a multifunctional protein that has manic roles in cell adhesion and signaling, among other things. Ectodomain of mCEACAM1 has four established causes of IgM such as domains, N, A1, B, and A2. The mCEACAM1’s N-terminal N field shares the MHV connection (Belouzard et al., 2012).

**The intervention of the virus at the site of binding of receptors**

The entry of the encapsulated virus may occur directly on the cell surface after attachment to the receptor or after its absorption by the multiplication of cells with fusion in the endosomal chamber. The fusion of viral membranes with the host membranes occurs due to the large corresponding changes in the peak of the protein. Over time, coronaviruses modified their climax of proteins, resulting in a group of catalysts that would not activate their fusion. These matching changes will begin by binding to the receptor but may have additional catalysts such as pH acidification or protein activation (Cheng et al., 2004).

**Table II. Different types of receptors proteins presence of different coronavirus species**

<table>
<thead>
<tr>
<th>Classes of Virus</th>
<th>Species</th>
<th>Receptor</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-CoV</td>
<td>TGEV</td>
<td>Aminopeptidase N (APN)</td>
<td>Delmas et al., 1992</td>
</tr>
<tr>
<td></td>
<td>CCoV</td>
<td>APN</td>
<td>Benbacer et al., 1997</td>
</tr>
<tr>
<td></td>
<td>FeCoV</td>
<td>APN</td>
<td>Tresnan et al., 1996</td>
</tr>
<tr>
<td></td>
<td>PEDV</td>
<td>APN</td>
<td>Li et al., 2007</td>
</tr>
<tr>
<td></td>
<td>HCoV-229E</td>
<td>APN</td>
<td>Yeager et al., 1992</td>
</tr>
<tr>
<td></td>
<td>HCoV-NL63</td>
<td>Angiotensin-converting enzyme 2 (ACE2)</td>
<td>Hofmann et al., 2005</td>
</tr>
<tr>
<td>β-CoV</td>
<td>BCoV</td>
<td>N-acetyl-D-9-O-acetylneuraminic acid</td>
<td>Schultze &amp; Herrler, 1992</td>
</tr>
<tr>
<td></td>
<td>MHV</td>
<td>Murine carcinoembryonic antigens related adhesion molecule 1 (mCEACAM) ACE2</td>
<td>Nedellec et al., 1994; Williams et al., 1991</td>
</tr>
<tr>
<td></td>
<td>SARS-CoV</td>
<td>Dipeptidyl peptidase (DPP4)</td>
<td>Li et al., 2003</td>
</tr>
<tr>
<td></td>
<td>MERS-CoV</td>
<td>Dipeptidyl peptidase (DPP4)</td>
<td>Raj et al., 2013</td>
</tr>
</tbody>
</table>
Integration of viral DNA into the host cell
The primary association of virion with the host cell begins with interactions between protein S and its receptor. Recipient binding domain (RBD) sites within the S1 protein S site of the coronavirus vary depending on the virus, some have RBD at the end N of S1 (MHV), while others SARS-CoV have an RBD at the C term of S1 (Krijnse-Locker et al., 1994). The interaction of S protein receptors is the primary determinant of coronaviruses to infect host species and also leads to polarization of the virus tissue. SARS-CoV and HCoV-NL63 use the ACE2 as a receptor, enter the MHV via mCEACAM1, and connect the newly identified MERS-CoV with dipeptidyl peptidase 4 (DPP4) to enter human cells as presented in Table II.

Repetition
The next step in the life cycle of a coronavirus is to translate the mimic gene from the viral genomic RNA. The gene codes for two large ORFs, rep1a and rep1b, which connect to two homogeneous polypropylene proteins, pp1a and pp1ab. To deliver multiple proteins, the virus uses a sliding sequence (5'-UUUAAC-3') and RNA pseudoknot that causes the displacement of the ribosome frame from the rep1a reading frame towards the ORF rep1b. In most cases, the ribosome breaks down the pseudoknot structure and extends the translation until it satisfies colonic stop code 1. Sometimes, the false node prevents the ribosome from continuing to elongate, resulting in a temporary stop in the slippery sequence, adjusting the reading frame by moving the nucleotide, and turning-1 frame before the ribosome can dissolve the pseudoknot structure and extend the translation to rep1b, which leads to an interpretation of pp1ab (Cheng & Shan, 2020; Yu et al., 2004).

![Figure 5. Replication process of SARS-CoV-2](image-url)
Destruction of type 2 respiratory pneumocyte cell
Viral particles transcribed into the respiratory type 2 lung cell begin to form buds forming the cell wall of the host cell. When these particles separate from the affected host cell, they damage part of the cell membrane of the host cell and cause the host cell to die by programmed cell death.

Viral spread
After reproduction and synthesis of RNA without genome, viral structural proteins S, E, and M are translated and inserted into the endoplasmic reticulum (ER). These proteins travel along the secretory pathway in the endoplasmic reticulum - Golgi compartment (ERGIC) (Tooze et al., 1984; de Haan & Rottier, 2005). There, viral genomes coated with N protein in ERGIC membranes contain viral structural proteins, forming mature virions (Arons et al., 2020).

SYMPTOMS OF COVID-19
The maximum number of patients infected with the virus will suffer from colds and influenza, while a few will remain asymptomatic. About 80% of patients will experience mild symptoms of the disease. Adults have the best immunity to fight infection, but the disadvantage is that they are more likely to spread infection and a recent study of nearly 140 patients at Zhong nan Hospital of Wuhan University has revealed two different. Types of symptoms that lead to a disease known as COVID-19. Almost 99% of the patients developed a very hot fever, while more than half of them experienced fatigue and a dry cough. A third of the patients developed a dry cough and difficulty breathing (Yi et al., 2020; Fu et al., 2020).

DIAGNOSIS OF COVID-19
The diagnosis allows suspects to understand whether they are infected or not. Diagnosis can help get the care they need and can help them take steps to reduce the likelihood of injury to others. If a person develops symptoms of coronavirus 2019 and is exposed to the virus, he consults a doctor. The doctor can decide whether or not to test COVID-19 based on individual signs and symptoms. The doctor can also determine if the person is in close contact with a person diagnosed with COVID-19 or who has visited or lived in areas where the community has continued to spread COVID-19 in the past 14 days (Jin et al., 2020).

Direct detection
The SARS-CoV-2 infection is detected by special laboratory tests that require samples such as throat swabs or lung fluid. This method is called a PCR test and it takes 24 to 48 hours to get the final results. WHO recommends sampling the upper and lower respiratory tract. This can be done with sputum, bronchial lavage, or end-trachea sucking. These samples will then determine the viral RNA identity using a polymerase chain reaction (PCR). If a positive test result is obtained, it is recommended to repeat the activation test. Negative tests with strong clinical suspicion are also recommended for repeated testing (Kumar et al., 2020; Hassan et al., 2020).

Serological test
The SARS-CoV ELISA and IgM ELISA Inner control kits were developed using IDR 3 N SARS-CoV as antigens, which share 90% amino acid alkene identity with all or all SARSr-CoVs2. For IgG analysis, the 96-well MaxiSorp Nunc-Immuno ELISA sheet (100 ng per well) was coated overnight with recombinant N protein. Human sera are used at 1:20 dilution for one hour at 37°C. Monoclonal antibody IgG HRP (Kyab Biotech) was used at a dilution of 1 : 40000. OD value (calculated 450-630 nm). For IgM analysis, the 96-well MaxiSorp Nunc-Immuno ELISA sheet (500 ng per well) was coated overnight using anti-human IgM (μ series). Human sera are used at 1 : 100 dilutions for 40 minutes at 37°C, and then incubated with
anti-Rp. 3 N HRP (Kyab Biotech) antibodies at 1: 4,000 dilutions. OD values (450) - 630 nm) are calculated (Okba et al., 2020).

**RNA vaccines**

Modern Biotechnology Company in Cambridge has prepared a test vaccine for coronavirus diagnosis. This rapid change is due to the unique advantages of RNA vaccines, says MIT Professor Daniel Anderson that the main advantage of the RNA message is the speed with which you can define and use a new sequence to find a new vaccine (World Health Organization, 2020).

**Molecular examinations**

Currently, many of the tests that reveal SARS-CoV-2 are prepared internally, commercially, or under development. Some tests can only detect the new virus, and some tests can also detect other strains that are genetically similar (Trafton et al., 2020).

**TREATMENT OF COVID-19**

Currently, there is no specific treatment, vaccine, or drug for the virus. However, healthcare professionals have many ways to help patients. First, early diagnosis helps stop the spread of the disease, making society a safer place for everyday life. Second, there are supportive care options that seem to work miracles with new coronavirus patients.

**General treatment**

A confirmed COVID-19 patient needs complete bed rest and supportive treatment, ensuring that enough calories and fluids are consumed to reduce the risk of dehydration. Water and homeostasis must be maintained while monitoring vital signs and oxygen saturation; keep the airways clean and inhale the oxygen in more severe cases; Measure blood count, creative protein, urine test and other biochemical blood clues, including liver and kidney functions, group of heart muscle enzymes, and clotting function depending on patient conditions. Chest imaging should be reviewed continuously, and blood gas should be analyzed if necessary (Zhejiang University School of Medicine, 2020).

**Symptomatic treatment**

Control measures are needed for patients with a high fever. Antipyretic treatment should be done if the temperature exceeds 38.5°C. Warm baths and antipyretic stains are preferred as a precautionary measure to reduce the temperature. Common medications include oral ibuprofen, 5-10 mg/kg each; Oral acetaminophen, 10 to 15 mg/kg at a time (Zhejiang University School of Medicine, 2020).

**Oxygen therapy**

The risk of hypoxia increases when the virus targets the lungs. A nasal catheter and an oxygen mask should be provided to the patient immediately. In an emergency, non-invasive or invasive mechanical ventilation should be provided to the patient (Shen et al., 2020).

**Antiviral drugs**

Various antiviral drugs, including interferon-alpha (IFN-α), lopinavir/ritonavir, chloroquine phosphate, ribavirin, and arbidol are therapeutically useful for the prevention, diagnosis, and treatment of new induced pneumonia by SARS-CoV-2 by the National Health Committee (CNS) of the People's Republic of China For the temporary treatment of COVID-19. IFN-α is a widespread antiviral that is usually used to treat hepatitis, although it has been reported to prevent SARS reproduction in CoV in vitro. IFN-α is given as a vapor twice a day. Fifth editions of the guidelines approved antiviral drugs including IFN-α, lopinavir/ritonavir, and ribavirin for the treatment of COVID-19. Chloroquine is incorporated in the sixth version of the guidelines based on preliminary results of clinical studies. The specific method for administering IFN-α is the inhalation of vapor at a dose of 5 million units.
(and 2 ml of sterile water for injection) for adults, twice a day. The dose of lopinavir/ritonavir is 400 mg/100 mg for adults, twice daily. Ribavirin should be administered by intravenous infusion at a dose of 500 mg for adults, 2-3 times/day in combination with IFN-α or lopinavir/ritonavir. Oral chloroquine phosphate is administered in a dose of 500 mg (300 mg of chloroquine) for adults, twice a day. Arbidol is given orally at a dosage of 200 mg for adults, three times/day. The duration of treatment does not exceed 10 days (Zhang et al., 2020b; Wu et al., 2020b).

Favipiravir is a new drug in clinical trials for the treatment of COVID-19. On February 15th, 2020, China agreed that it was a useful drug for treating the new flu. It works by inhibiting the enzyme-dependent RNA polymerase RNA. Favipiravir is transformed into an active phosphorylate (favipiravir-RTP) form in cells and is recognized as a substrate by viral RNA polymerase, thereby inhibiting the activity of RNA polymerase. Therefore, favipiravir may have a potent antiviral effect on SARS-CoV-2, which is the RNA virus (Yavuz & Unal, 2020).

Remdesivir is another investigative drug in the clinical trial for the treatment of COVID-19. Remdesivir is a broad-spectrum nucleoside and antiviral analog. Animal experiments have indicated that remdesivir can effectively reduce viral load in lung tissue in mice infected with MERS-CoV virus, improve lung function and reduce pathological damage to lung tissue (Wu et al., 2020b; Cao et al., 2020).

A team of researchers from the Shanghai Materia Medica Institute and the Shanghai University of Technology conducted silicon drugs and enzyme activity testing and reported 30 workers who might have antiviral activity against SARS-CoV-2 on January 25th, 2020. These factors are indinavir, saquinavir, lopinavir, Carfilzomib, ritonavir, remdesivir, atazanavir, darunavir, tipranavir, fosamprenavir, enzaplantovir, presatovir, abacavir, bortezomib, cyclosporine A and cinanserin. It has also been proven that some Chinese herbal medicines such as Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis contain certain active ingredients that were effective against COV-2 (Shen et al., 2020).

**Antibiotic drugs**

The third class of medicinal drugs is Azithromycin, a class of antibiotics known as macrolide that is used to treat infections such as bronchitis, pneumonia, and MAC infection (Mycobacterium avium complex). With the spread of SARS-CoV-2, many countries around the world have started developing countermeasures to limit the spread of the disease. The authors found that in addition to hydroxychloroquine, another FDA-approved drug known as Azithromycin had therapeutic effects against COVID-19 in a study accompanied by a University of New Mexico research group (Choudhary & Sharma, 2020).

**Anti-coagulating therapy**

Hospital patients with severe medical illness are at an increased risk of developing VTE up to 90 days after discharge. This result should apply to COVID-19 patients, although infection data don't seem to be yet available. Therefore, it is reasonable to think of long blood clots occurring after prolonged discharge using a regulated approved system (such as betrixaban 160 mg on the first day, followed by 80 mg once daily for 35 to 42 days; or rivaroxaban 10 mg daily for 31 to 39 Days) (Porfidia & Pola, 2020).

**Boosts the immune system**

In addition to basic disease prevention and true defense, there is a strong immune system. The human body is better able to fight disease when the immune system is impulsive and people have to get fit to get the perfect shape. In this critical condition, get enough sleep and a little fresh air and the sun every day. People also need to
stay hydrated, reduce excessively processed foods, and make sure to eat enough micronutrients when they can do their best with what they can find in grocery stores right now (Taghizadeh-Hesary & Akbari, 2020).

**PREVENTION AND CONTROL OF COVID-19**

This new virus often features a limited geographic spread (Zappa et al., 2009). However, there are the amounts of hygiene measures that are recommended to guard against the infection and for the spread the include following advisory are covering your mouth and nose with masks, avoiding close contact with those that are sick, stop shaking hand with one other, washing hands regularly after one hour with soap, avoiding unnecessary contact with animals and hand washing, use of masks and PPE (Personal protective equipment), drinking warm water daily, sanitize your hands time to time (Singhal, 2020).

**Steps to protect yourself**

1. Wash your hands regularly and completely with soap and water for at least 20 seconds or with an alcohol-based hand sanitizer (a hand sanitizer that contains at least 60% alcohol), rub the cover thoroughly together so that it does not dry out, especially after visiting a public place, or after blowing your nose or sneeze as well as cough.
2. Hands touch many surfaces and catch viruses, and these contaminated hands can spread the virus to your nose, eyes, or mouth. So, avoid touching these organs with unwashed hands. Because from there, the virus can enter the body and make people sick.
3. Maintain a social distance (keep at least 1 m or 3 feet between you and anyone) and avoid close contact with patients (who cough or sneeze). When infected or sneeze, they spray small drops from their nose or mouth that may contain the COVID-19 virus. A person can breathe these drops (Centers for Disease Control and Prevention, 2020).

**Steps to protect others**

1. Stay home if you are not feeling well unless you will get medical treatment.
2. If you have a cough, fever, and difficulty breathing, see your doctor online, see your doctor.
3. If you are sick, avoid using public transportation.
4. When you cough or sneeze, cover your mouth and nose with a tissue.
5. Throw used tissue into the trash and wash your hands immediately with cleansing water and soap.
6. If possible, stay isolated in a room separate from family and pets and wear a face mask when you are with other people (for example, sharing a room or car). If you are unable to wear a face mask (for reasons related to breathing difficulties or for any other reason), you cover coughs and sneezes, but when people caring for you enter your room they should wear a face mask (face masks may be low in width and should be kept for caregivers).
7. Stay home for some time and follow your doctor's instructions.
8. If you are sick, avoid sharing bedding, dishes, glasses, and other household items.
9. Use a separate bathroom and toilet, if possible.
10. If the surfaces are dirty, clean them and use detergents or antiseptic soaps and water before using the disinfectant,
11. Apply antiseptic daily to frequently affected surfaces. This includes offices, telephones, keyboards, toilets, faucets, tables, door handles, lighting switches, counters, knobs, and basins.
12. Identify and isolate suspected cases.
13. Before starting clinical care, identify potential cases as soon as possible and isolate suspects separately from those who have confirmed cases of COVID-19, to
prevent the possible transmission of infection to other patients and nursing staff.

14. Avoid direct physical contact (including physical examination and exposure) to other respiratory and physical secretions. For example, move the possibility of infectious people into isolation rooms and close the doors. In the workplace, make the distance between workers, clients, and other visitors, especially from the location of potentially infectious people.

15. If there is a need to isolate a patient or a group of patients, pharmacies must determine and prepare an appropriate space.

16. Most patients coming to community pharmacies are unlikely to have COVID-19. If you have symptoms of a cough, cold, or flu-like symptoms, but not related to COVID-19, or the date of travel or contact, pharmacies should do so following their best practices and routine infection risk management. Across to other employees and patients.

17. Restrict the number of individuals entering isolation areas, including the bedroom of a patient with suspected and confirmed COVID-19.

18. To practice safe work, protect workers from close contact with the affected person using additional technical and administrative controls (Occupational Safety and Health Administration, 2020).

CONCLUSION

The COVID-19 pandemic is traveling around the world at a dangerous rate. More infections and deaths are caused by SARS or ME respiratory syndrome. The R0 values supported, SARS-CoV-2 assumed more SARS or MERS infection. The elderly and HIV-positive patients are at greater risk of death. The first outbreak requires extensive surveillance and isolation protocols to stop transmission. No confirmed drugs or vaccines were developed. The first treatment strategies are aimed at symptomatic care and oxygen therapy. Preventive vaccination is necessary for the long-term prevention of epidemics or epidemics associated with the coronavirus.

ACKNOWLEDGMENT

The authors would like to express our deep gratitude to all those who helped us directly and indirectly in the realization of the work of this review article.

REFERENCES


Bhardwaj, K., Guarino, L., & Kao, C.C. (2004). The Severe Acute Respiratory Syndrome Coronavirus Nsp15 Protein Is an Endoribonuclease That


